RxDoctor Payments Data

John Staniland, MD

Family Medicine · Fort Worth, TXNPI 1447264908

Payments from drug & device makers

$4,276in general payments, 2019–2025

Across 251 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$677
  • AbbVie$458
  • Lilly USA, LLC$366
  • Amarin Pharma, Inc.$307
  • Antares Pharma, Inc.$231
  • GSK$198
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,256100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,276 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$53,295
Medicare patients
245
Services billed
2,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$122,700
EliquisApixaban51$50,973
TrulicityDulaglutide39$47,019
Liothyronine Sodium894$44,153
JanumetSitagliptin Phos/Metformin Hcl39$36,325
Tresiba Flextouch U-200Insulin Degludec47$35,393
Tresiba Flextouch U-100Insulin Degludec44$29,488
MounjaroTirzepatide25$24,393
JanuviaSitagliptin Phosphate18$20,109
FarxigaDapagliflozin Propanediol18$19,780
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$19,211
LinzessLinaclotide16$16,139
RybelsusSemaglutide12$15,911
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,041
MyrbetriqMirabegron15$11,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$677$138,611110 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$366$76,06778 claims
MerckJanumet, Januvia, Belsomra$74$61,44268 claims
PfizerEliquis, Premarin$34$54,88766 claims
AstraZenecaFarxiga, Breztri Aerosphere$147$31,82237 claims
AbbVieLinzess, Armour Thyroid$458$21,73792 claims
GSKTrelegy Ellipta$198$19,21116 claims
Astellas Pharma US IncMyrbetriq$77$11,37115 claims
Acella Pharmaceuticals, LLCNp Thyroid$53$8,681109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →